Clinical Trials | June 09, 2026
AbbVie showcases broad blood cancer pipeline at EHA 2026 with 21 presentations
The company will present 21 oral and poster presentations spanning investigational and approved therapies
The company will present 21 oral and poster presentations spanning investigational and approved therapies
The campaign places renewed focus on a disease that remains incurable despite major scientific advances
Researchers say the results point to a potential shift in how obesity is treated—as a central disease driving multiple conditions, rather than a collection of separate problems
We are building the bridge between complex molecular data and everyday clinical decisions
Veteran healthcare leader with extensive experience in hospital operations will drive operational excellence, patient-centric care, and sustainable growth in his new role
The program expected to commence in August 2026 will be offered across multiple specialised areas with an intake of 20-30 students per course
Veteran pharma and biotech executive brings over 20 years of commercial leadership experience to support LMS's global CDMO and API growth strategy
Community healthcare initiatives reach a milestone year, with services spanning 90 districts, 22 states, and over 70 lakh cumulative beneficiaries since 2006
The session created a platform for meaningful discussions on the challenges of the disease and the importance of timely intervention
Exclusive Asia-Pacific licensing agreement for Bejescin strengthens the company’s nephrology and autoimmune disease portfolio
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
